Allogene Therapeutics (NASDAQ:ALLO) Price Target Raised to $10.00

Allogene Therapeutics (NASDAQ:ALLO) had its price objective hoisted by Jefferies Financial Group from $6.00 to $10.00 in a research note published on Monday, Marketbeat.com reports. The firm currently has a buy rating on the stock.

A number of other research firms also recently commented on ALLO. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 13th. Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Citigroup reiterated an “outperform” rating on shares of Allogene Therapeutics in a report on Tuesday. Argus upped their price objective on Allogene Therapeutics from $1.60 to $3.85 and gave the company a “market perform” rating in a report on Tuesday. Finally, Sanford C. Bernstein upped their price objective on Allogene Therapeutics from $1.60 to $3.85 and gave the company a “market perform” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.44.

Allogene Therapeutics Trading Down 4.8%

NASDAQ ALLO opened at $2.17 on Monday. The stock has a 50-day simple moving average of $2.31 and a 200 day simple moving average of $1.72. The company has a market capitalization of $529.00 million, a PE ratio of -2.49 and a beta of 0.53. Allogene Therapeutics has a 12 month low of $0.86 and a 12 month high of $4.46.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.08. As a group, sell-side analysts predict that Allogene Therapeutics will post -1.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Allogene Therapeutics news, SVP Earl Martin Douglas sold 22,900 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.76, for a total value of $40,304.00. Following the completion of the sale, the senior vice president directly owned 564,948 shares in the company, valued at $994,308.48. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David D. Chang sold 47,763 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $2.47, for a total value of $117,974.61. Following the completion of the sale, the chief executive officer owned 5,150,599 shares of the company’s stock, valued at $12,721,979.53. This trade represents a 0.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 278,452 shares of company stock valued at $534,053 over the last ninety days. 13.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Allogene Therapeutics

Several large investors have recently modified their holdings of ALLO. AQR Capital Management LLC bought a new stake in shares of Allogene Therapeutics in the first quarter worth about $85,000. Goldman Sachs Group Inc. increased its holdings in shares of Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after acquiring an additional 3,747,397 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Allogene Therapeutics by 578.7% in the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after acquiring an additional 952,158 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Allogene Therapeutics by 13.0% in the second quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock worth $4,289,000 after acquiring an additional 435,389 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Allogene Therapeutics by 14.0% during the second quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock worth $237,000 after buying an additional 25,628 shares in the last quarter. 83.63% of the stock is currently owned by institutional investors.

Key Allogene Therapeutics News

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: Nature Communications published pre‑clinical data on ALLO‑329 (a dual CD19/CD70 AlloCAR‑T for autoimmune disease), validating pipeline progress and supporting longer‑term value of non‑oncology programs. Article Link
• Positive Sentiment: Early ALPHA3 data (cema‑cel) showed strong MRD clearance in first‑line LBCL, a clinically meaningful signal that boosted investor optimism about near‑term commercialization or partnership potential. Article Link
• Positive Sentiment: Analyst bullishness is increasing — Jefferies raised its price target to $10 and set a Buy, joining several other recent upgrades and higher targets that support upside expectations. Article Link
• Positive Sentiment: Unusually high call‑option activity suggests speculative bullish positioning or hedging tied to the recent clinical/upgrade news. Article Link
• Neutral Sentiment: Multiple firms adjusted price targets upward (Baird, Citizens, Argus, etc.), increasing analyst attention but with a wide range of targets (near‑term execution risk remains).
• Neutral Sentiment: Company commentary and coverage include discussion of an interim futility analysis from the pivotal Phase II ALPHA3 trial; such analyses can move markets depending on final interpretation but are informational until formal readouts. Article Link
• Negative Sentiment: Allogene priced a large public offering of 87.5M shares at $2.00 (≈$175M gross) with an underwriter option for more — immediate dilution and press for the stock at a low price is the main headwind weighing on the share price. Article Link
• Negative Sentiment: Unusual put buying (4,437 put contracts, ~356% above normal daily put volume) points to hedging or bearish bets by some traders, adding downside pressure/volatility.
• Negative Sentiment: Recent insider selling (multiple exec sales noted in public filings) and mixed institutional repositioning can amplify negative sentiment around the offering and near‑term funding needs.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.